Table 1.
Overview of the diagnosis and treatment of common community acquired respiratory viral infections in solid organ transplant recipients
| Virus | Diagnostic test (s) | Treatment (s) |
|---|---|---|
| Respiratory syncytial virus | Antigen detection | Upper respiratory tract & no risk factors: |
| Nucleic acid detection | Supportive care | |
| Viral culture | Upper respiratory tract & risk factors or | |
| Shell vial culture | Lower respiratory tract: | |
| Aerosolized ribavirin in combination with RSV IVIG or pavilizumab should be considered (BIII) | ||
| Influenza | Viral culture | Influenza A infection: |
| Shell vial culture | amantadine, rimantadine, zanamivi | |
| Antigen detection | and oseltamivir (BIII) | |
| Influenza B infection: zanamivir and oseltamivir (BIII) | ||
| Consider addition of aerosolized ribavirin for severe lower respiratory tract disease (CIII) | ||
| Parainfluenza | Viral culture | Upper respiratory tract infection: |
| Shell vial culture | Supportive care | |
| Antigen detection | Lower respiratory tract infection: | |
| Nucleic acid detection | Supportive care | |
| Consider aerosolized ribavirin (CIII) as no other options but experience to date provides little evidence for likely efficacy | ||